Ann: Activities Report and Appendix 4C - June 2023 Quarter, page-15

My context, here, was really based off the "4+13" chart in the Telix presentation where they mark off the ProstACT SELECT trial as "done." So, in terms of major milestones- particularly revenue generating- in the near term, those are the two big things for me.

I'm writing this having listened to the audio from the business update (I wasn't able to listen this morning), and one of the the things that stuck out to me was the way therapy was emerging across the board (STARLITE, IPAX and of course PROSTACT). So I take your point that, longer term, therapy trials getting under way matter a lot.

I've said before that I think there's a good chance that the CAIX thread with 250 (I wonder when we'll get a product name for that) and trials such as STARBURST and STARSTRUCK (and STARLITE I imagine, that threads been going for a while now) will be the jewel in the crown. Really great to hear those are making progress

I'm intrigued by the whole "Illucix 2.0" comment, we'll see what that means in due course I suppose.